Alphamab Oncology announced that with effect from March 30, 2021, Mr. XU Weihao ("Mr. Xu") has been appointed as their chief financial officer, who will be primarily responsible for the formulation of the Company's financial and capital market strategy and investor relations matters, as well as participate in the Company's international business expansion and cooperation. Dr. Nippgen has over 25 years of experience in medical industry. His industry expertise covers the clinical research and development and as well as project management in various international biopharma and biotech companies. From 2018 to 2021, he served as head of research and development in China at Merck Group. Prior to that, he served as a leader of research and development program at Merck KGaA, Karyopharm Therapeutics Inc., and Glycotope GmbH. From 1994 to 2004, he worked at Universitätsklinikum Carl Gustav Carus, primarily responsible for surgical oncology and urology.